In the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): An improved method for cancer therapy, comprising:

administering the combination of a cytokine-expressing cellular vaccine and at least one additional cancer therapeutic agent selected from the group consisting of ~~an anti-CTLA4 antibody,~~ an anti-4-1BB antibody, interferon-alpha, docetaxel, paclitaxel, a COX-2 inhibitor, an anti- CD40 antibody or CD40 ligand, an anti-OX40 antibody or OX-40 ligand and a heat shock protein (HSP), to a subject with cancer, wherein administration of the combination to the subject results in enhanced therapeutic efficacy relative to administration of the cytokine-expressing cellular vaccine or the at least one additional cancer therapeutic agent alone.

2. (Original): The method of claim 1, wherein the cytokine-expressing cellular vaccine expresses GM-CSF.

3. (Original): The method of claim 2, wherein the cells of said cytokine-expressing cellular vaccine are autologous to the subject.

4. (Original): The method of claim 2, wherein the cells of said cytokine-expressing cellular vaccine are allogeneic to the subject.

5. (Original): The method of claim 2, wherein the cells of said cytokine-expressing cellular vaccine cells are bystander cells.

6. (Original): The method of claim 2, wherein the cells of the cytokine-expressing cellular vaccine are rendered proliferation-incompetent by irradiation.

7. (Original): The method of claim 2, wherein the mammal is a human.

8. (Original): The method of claim 2, wherein the cancer is a prostate cancer.

9. (Original): The method of claim 2, wherein the cancer is a non-small cell lung carcinoma.

10. (Original): The method of claim 4, wherein the allogeneic cells are a tumor cell line selected from the group consisting of a prostate tumor line, a non-small cell lung carcinoma line and a pancreatic cancer line.

11. (Cancelled)

12. (Original): The method of claim 2, wherein said at least one additional cancer therapeutic includes an anti-4-1BB antibody.

13. (Original): The method of claim 2, wherein said at least one additional cancer therapeutic agent includes interferon-alpha.

14. (Original): The method of claim 2, wherein said at least one additional cancer therapeutic agent includes docetaxel or paclitaxel.

15. (Original): The method of claim 14, wherein said at least one additional cancer therapeutic agent includes docetaxel.

16. (Original): The method of claim 2, wherein said at least one additional cancer therapeutic agent includes a COX-2 inhibitor.

17. (Original): The method of claim 16, wherein said COX-2 inhibitor is Celecoxib.

18. (Original): The method of claim 2, wherein said at least one additional cancer therapeutic agent includes an anti-CD40 antibody or CD40 ligand.

19. (Original): The method of claim 2, wherein said at least one additional cancer therapeutic agent is expressed by a cell and the cell is an autologous, allogeneic or a bystander cell.

20. (Original): The method of claim 19, wherein the autologous, allogeneic or a bystander cell is rendered proliferation-incompetent by irradiation.

21. (Original): The method of claim 20, wherein the autologous, allogeneic or a bystander cell expresses interferon-alpha.

22. (Original): The method of claim 20, wherein the autologous, allogeneic or a bystander cell expresses CD40 ligand.

23. (Original): The method of claim 2, wherein said cytokine-expressing cellular vaccine is administered subcutaneously.

24. (Original): The method of claim 2, wherein said cytokine-expressing cellular vaccine is administered intratumorally.

27. (Original): The method of claim 16, wherein said COX-2 inhibitor is administered before the GM-CSF-expressing cellular vaccine.

26. (Original): The method of claim 18, wherein said anti-CD40 antibody is administered after the GM-CSF-expressing cellular vaccine.

27. (Original): The method of claim 18, wherein said CD40 ligand is administered after the GM-CSF-expressing cellular vaccine.

28. (Currently Amended): An improved composition for cancer therapy, comprising:

a GM-CSF expressing cellular vaccine and at least one additional cancer therapeutic agent selected from the group consisting of ~~an anti-CTLA4 antibody,~~ an anti-4-1BB antibody, interferon-alpha, docetaxel, Celecoxib, an anti- CD40 antibody and CD40 ligand for administration to a subject with cancer, wherein administration of the combination results in enhanced therapeutic efficacy relative to administration of the GM-CSF expressing cellular vaccine or the at least one additional cancer therapeutic agent alone.

29. (Original): The composition of claim 28, wherein the cells of said cytokine-expressing cellular vaccine are autologous to the subject.

30. (Original): The composition of claim 28, wherein the cells of said cytokine-expressing cellular vaccine are allogeneic to the subject.

31. (Original): The composition of claim 28, wherein the cells of said cytokine-expressing cellular vaccine cells are bystander cells.

32. (Original): The composition of claim 28, wherein the cells of said cytokine-expressing cellular vaccine are rendered proliferation-incompetent by irradiation.

33. (Original): The composition of claim 30, wherein said allogeneic cells are a tumor cell line selected from the group consisting of a prostate tumor line, a non-small cell lung carcinoma line and a pancreatic cancer line.

34. (Cancelled)

35. (Original): The composition of claim 28, wherein said at least one additional cancer therapeutic is an anti-4-1BB antibody.

36. (Original): The composition of claim 28, wherein said at least one additional cancer therapeutic agent is interferon-alpha.

37. (Original): The composition of claim 28, wherein said at least one additional cancer therapeutic agent is docetaxel.

38. (Original): The composition of claim 28, wherein said at least one additional cancer therapeutic agent is Celecoxib.

39. (Original): The composition of claim 28, wherein said at least one additional cancer therapeutic agent is an anti-CD40 antibody or CD40 ligand.

40. (Original): The composition of claim 28, wherein said at least one additional cancer therapeutic agent is expressed by a cell and the cell is autologous, allogeneic or a bystander cell.

41. (Original): The composition of claim 40, wherein the autologous, allogeneic or bystander cell is rendered proliferation-incompetent by irradiation.

42. (Original): The composition of claim 41, wherein the autologous, allogeneic or a bystander cell expresses interferon-alpha.

43. (Original): The composition of claim 41, wherein the he autologous, allogeneic or a bystander cell expresses CD40 ligand.